| Nov 20 |
Coya Therapeutics files to sell 1.38M shares of common stock for holders
|
| Nov 19 |
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
|
| Nov 6 |
Coya Therapeutics GAAP EPS of -$0.26
|
| Nov 6 |
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results
|
| Nov 1 |
Coya Therapeutics names Arun Swaminathan as CEO
|
| Nov 1 |
Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer
|
| Oct 31 |
Coya Therapeutics: Buying The Dip After Unwarranted Sell-Off
|
| Oct 30 |
Coya Therapeutics Reports Positive Phase 2 Alzheimer’s Trial Results
|
| Oct 29 |
Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study
|
| Oct 29 |
Coya stock tumbles 23% on mixed results from Alzheimer's study
|
